
Neoadjuvant PAXG Outperforms mFOLFIRINOX in Resectable and Borderline Resectable PDAC
Final results of the phase 3 CASSANDRA trial (NCT04793932) demonstrated that PAXG (cisplatin, nab-paclitaxel, gemcitabine, and capecitabine) is superior to modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant chemotherapy for the treatment of patients with …